Welcome to RadMD, Radiology in Medical Development

Welcome

RadMD is the source to provide radiologists for medical development.

Medical imaging, as a surrogate marker for efficacy, has become an important tool in the development of pharmaceutical and medical devices. As imaging can provide an early indication of drug response , drug and device companies are increasingly incorporating imaging in both preclinical and clinical development programs. This can result in a net reduction of overall development costs and shorten drug development time. In addition, imaging can be used to provide a better understanding of disease processes and define potential therapeutic targets.

The FDA and international regulatory bodies continue to expand advocacy of medical imaging surrogate endpoints in clinical trials. As a result, more clinical trials include medical imaging endpoints than ever before. Images generated during a clinical trial require independent evaluation, i.e. “blinded reading”. The number of these blinded reads has more than quadrupled in the US in the last 5 years. Blinded reads are often performed at centralized imaging contract research organizations (ICRO’s) labs. Completing a blinded read on schedule is critical for the sponsor to submit their drug/device for regulatory approval within timelines. Delays in performing a blinded read can significantly in bringing new drugs and devices to the market.
With increasing utilization of imaging in clinical trials has come a greater demand for qualified radiologists to participate as blinded readers of imaging data. However, finding qualified radiologists available to perform an ever-increasing number of blinded reads has become problematic.

RadMD has recognized this problem and has developed a worldwide database of board certified, highly qualified radiologists to participate as blinded readers in clinical trials. Our unique SMaRT™ database ( Seamless Management of Radiologists for Trials) includes pertinent professional information about each radiologist, including his/her education and qualifications; clinical and research experience; area(s) of expertise; prior participation in clinical trials and blinded reads; and other relevant information required by regulatory authorities and sponsors . Each radiologist is pre-qualified by RadMD prior to inclusion in the SMaRT database. SMaRT™ is a global resource, and includes RadMD-vetted radiologists in North and South America, Europe, and Asia.
It is the extent and depth of our database of expert radiologists which allows us to readily identify and match physicians whose qualifications are optimal for performing a particular blinded read.

Read Drs. Patt and Shamsi's correspondence article in JCO

HOME | SERVICES | WHO WE ARE | HOW WE WORK | REGISTER

telephone: 610.847.2333 • fax: 610.482.9332 • charris@rad-md.net
PO Box 20, Pipersville, PA 18947 • Admin Login

RAD-MD©2006.

Welcome

RadMD is the source to provide radiologists for medical development.

Medical imaging, as a surrogate marker for efficacy, has become an important tool in the development of pharmaceutical and medical devices. As imaging can provide an early indication of drug response , drug and device companies are increasingly incorporating imaging in both preclinical and clinical development programs. This can result in a net reduction of overall development costs and shorten drug development time. In addition, imaging can be used to provide a better understanding of disease processes and define potential therapeutic targets.

The FDA and international regulatory bodies continue to expand advocacy of medical imaging surrogate endpoints in clinical trials. As a result, more clinical trials include medical imaging endpoints than ever before. Images generated during a clinical trial require independent evaluation, i.e. “blinded reading”. The number of these blinded reads has more than quadrupled in the US in the last 5 years. Blinded reads are often performed at centralized imaging contract research organizations (ICRO’s) labs. Completing a blinded read on schedule is critical for the sponsor to submit their drug/device for regulatory approval within timelines. Delays in performing a blinded read can significantly in bringing new drugs and devices to the market.
With increasing utilization of imaging in clinical trials has come a greater demand for qualified radiologists to participate as blinded readers of imaging data. However, finding qualified radiologists available to perform an ever-increasing number of blinded reads has become problematic.

RadMD has recognized this problem and has developed a worldwide database of board certified, highly qualified radiologists to participate as blinded readers in clinical trials. Our unique SMaRT™ database ( Seamless Management of Radiologists for Trials) includes pertinent professional information about each radiologist, including his/her education and qualifications; clinical and research experience; area(s) of expertise; prior participation in clinical trials and blinded reads; and other relevant information required by regulatory authorities and sponsors . Each radiologist is pre-qualified by RadMD prior to inclusion in the SMaRT database. SMaRT™ is a global resource, and includes RadMD-vetted radiologists in North and South America, Europe, and Asia.
It is the extent and depth of our database of expert radiologists which allows us to readily identify and match physicians whose qualifications are optimal for performing a particular blinded read.

Read Drs. Patt and Shamsi's correspondence article in JCO

HOME | SERVICES | WHO WE ARE | HOW WE WORK | REGISTER

telephone: 610.847.2333 • fax: 610.482.9332 • charris@rad-md.net
PO Box 20, Pipersville, PA 18947 • Admin Login

RAD-MD©2006.